Department of Internal Medicine, Henry Ford Hospital, 2799 West Grand Boulevard, CFP-1, Detroit, MI 48202, USA.
Department of Gastroenterology and Hepatology, Henry Ford Hospital, 2799 West Grand Boulevard, K7, Detroit, MI 48202, USA.
Clin Liver Dis. 2020 May;24(2):303-315. doi: 10.1016/j.cld.2020.01.009. Epub 2020 Mar 2.
Despite widespread use of lactulose and rifaximin for the treatment of hepatic encephalopathy, this complication of advanced liver disease remains a major burden on the health care system in the United States and continues to predispose to high morbidity and mortality. Several agents have surfaced over recent years with promise to treat hepatic encephalopathy and mitigate the cognitive impairment associated with this disease process. The purpose of this article is to highlight the leading emerging therapies in hepatic encephalopathy as well as their therapeutic targets.
尽管乳果糖和利福昔明被广泛用于治疗肝性脑病，但这种晚期肝病的并发症仍然是美国医疗保健系统的一个主要负担，并继续导致高发病率和死亡率。近年来，有几种药物崭露头角，有望治疗肝性脑病并减轻与该疾病过程相关的认知障碍。本文的目的是强调肝性脑病的主要新兴疗法及其治疗靶点。
